CARDIFF LEXINGTON
CORPORATION



INVESTOR PRESENTATION

November 2025

OTCQB: CDIX

FORWARD LOOKING STATEMENTS

This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or subscribe for securities of Cardiff Lexington (the "Company") in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No securities commission or similar authority of the United States or any other jurisdiction has reviewed or in any way passed upon this presentation or the merits of the securities described herein, and any representation to the contrary is an offence. This presentation does not contain all of the information that would normally appear in a prospectus or registration statement under applicable United States securities laws. Readers should not construe the contents of this presentation as investment, legal, tax, regulatory, financial or accounting advice and are urged to consult with their own advisers in relation to such matters.

The Company does not make any representation or warranty (express or implied) as to the accuracy or completeness of the information in this presentation. Except as may be required by applicable law, the Company expressly disclaims any obligation to update any of the information contained herein or to inform readers of any matters of which it becomes aware that may affect any matter referred to in this presentation.

Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of management. Management believes that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.

Market data and certain industry data and forecasts included in this presentation were obtained from internal company surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. Where this presentation quotes any information or data from any third-party source, it should not be interpreted that the Company has adopted or endorsed such information or data as being accurate. The Company has not independently verified any of such information from third-party sources or any underlying assumptions. Accordingly, the Company makes no representation or warranty (express or implied) on the fairness, accuracy, completeness or correctness of any such third-party information.

This presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements as those statements that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including those described under the heading "Risk Factors" in the registration statements and reports that we file with the U.S. Securities and Exchange Commission. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.

CARDIFF LEXINGTON
CORPORATION

Cardiff Lexington is **building the next scalable healthcare** platform via a **high margin, lean-cost model driving profitability** and providing a foundation for **disciplined, acquisition-led expansion**

TARGETING AN UNDERSERVED PATIENT POPULATION WITH PROVEN RESULTS

By the Numbers

12

Nova Ortho and Spine locations throughout Florida & Georgia

$8.8M


GAAP Revenue: Nine Months Ended 9/30/25

20.5%

Net Operating Margin: Nine Months Ended 9/30/25

$1.9M

Adjusted EBITDA: Nine Months Ended 9/30/25



Expanding into the broader Southeast US through **organic growth & strategic M&A**

CARDIFF LEXINGTON CORPORATION

WELL POSITIONED FOR LONG-TERM GROWTH IN A FRAGMENTED MARKET PRIMED FOR CONSOLIDATION


- **Profitable & Scalable Healthcare Platform**
- **Fastest Growing Sector in US Healthcare**
- **Recession Resistant**
- **Underserved Patient Population**
- **Proven Growth & Capital Efficiency**
- **High Barrier to Entry & Fragmented Market**
- **Compelling Capital Deployment Opportunity**

"Cardiff Lexington has built a **profitable, credible, and scalable growth platform** supported by seasoned management, a **proven, capital efficient business model,** and the demonstrated ability to **deploy capital at a very high rate of return"**

- Alex Cunningham , CEO

ANNUAL REVENUE PERFORMANCE

(In Millions)



- **2025 YTD GAAP revenue of $8.8M** compared with $5.1M in the same period in 2024
- **2024 GAAP revenue impacted by one-time non-cash adjustments totaling $2.8M**
- **2024 adjusted revenue* consistent with 2023 levels** despite multiple week shutdown in 3Q24 related to Hurricane Helene
- **Annual GAAP revenue expected to increase** alongside M&A activity, enhanced operating capacity, and expanding Nova Ortho and Spine network

CARDIFF LEXINGTON CORPORATION

*Adjusted revenue is a non-GAAP metric that is reconciled to GAAP revenue in the appendix of this presentation

NOVA ORTHO AND SPINE REPRESENTS STRONG CORE BUSINESS

FULFILLING THE NEEDS OF AN UNDERSERVED MARKET

- **No dependence on CMS** (Medicare/Medicaid) **or health insurance companies** (HMOs or Blue Cross) for reimbursement
- **Payor mix** is almost exclusively comprised of automotive insurance companies, general liability carriers, and private pay

ATTRACTIVE ECONOMIC MODEL

- Longer A/R gestation period (typically 18-24 months) is accounted for in pricing of patient care
- **95%+ collection rate** over past three years

HIGH DEMAND

- Nova Ortho and Spine currently sees approximately **165-185 patients per month across 12 locations**
- **Robust referral network**

CAPACITY FOR SUBSTANTIAL ORGANIC GROWTH

- All locations **collectively operating at approximately 35% capacity**

PROVEN EXPERTISE

- **Management team with 25+ years' experience** operating primary, specialty and ancillary care facilities

SUPERIOR SERVICE AND ORTHOPEDIC CARE

Enabling critical access to high-quality care for traumatic injury patients

Patient-Centric Pathway

TRUSTED REFERRAL NETWORK

Patients are primarily referred through a growing network of trusted **physicians, physical therapists and chiropractors**

TRUE PARTNER THROUGH THE LIFECYCLE OF A CLAIM

Nova Ortho and Spine has **superior access to patient information** to case validity and manage each one appropriately

LEADER IN SURGICAL TECHNIQUES & TECHNOLOGY

Nova Ortho and Spine's team of surgeons and specialists deliver **cutting-edge treatment options at state-of-the-art facilities**


QUALITY CARE AT ZERO COST TO THE PATIENT

Revenue is primarily provided by bodily injury policies, general liability policies, and personal injury protection policies, which **protects patients from high upfront costs**

FAVORABLE EXTERNAL GROWTH DRIVERS

Higher healthcare costs, broader care modalities, and increasing claim frequency are driving strong and sustainable growth for specialized personal injury providers

12.5% increase in automobile accidents expected through 2028*



- Increasing interest by institutional capital is driving innovation and consolidation for the industry
- Regulatory landscape in many states is favorable for specialized personal injury providers
- Specialized and sophisticated providers are better suited to capture referral sources

CARDIFF LEXINGTON CORPORATION

*Statista; *Number of accidents and traffic-related injury rate in the U.S. per 1M people forecasted through 2028*

STRONG AND GROWING MARKET PRESENCE

12 Nova Ortho and Spine locations strategically positioned in population centers **throughout Florida and Georgia** with plans to **expand to broader southeast US**

- Okeechobee (FL)
- Fort Pierce (FL)
- Vero Beach (FL)
- Palm Bay (FL)
- Tallahassee (FL)
- Madison (FL)
- Sebastian (FL)
- Panama City Beach (FL)
- Port St. Lucie (FL)
- Orlando (FL)
- Chipley (FL)
- Valdosta (GA)

Florida has the most personal injury claims per capita[1]; Valdosta, Georgia location represents broader expansion into broader southeast U.S.

CARDIFF LEXINGTON CORPORATION

[1]Law.com; *New Study Finds Florida Has the Most Personal Injury Cases Per Capita. Is New Bad Faith Law to Blame?*

EXPANDING ADDRESSABLE MARKET THROUGH STRATEGIC M&A

Target Strong Core Cash Flows	Acquire Accretive Assets to Current Model	Drive Long-Term & Sustainable Profitability
Acquire, optimize, and manage physician practices with **strong cash flow prospects** to drive **recurring revenue and operational efficiencies**	**Expand geographical footprint through ownership of real estate** assets including Ambulatory Surgery Centers and orthopedic clinics	Acquire and manage personal injury practice accounts receivables to **capture long-term income and drive sustained profitability**

Cardiff Lexington is at a **strategic inflection point** and is well-positioned to **accelerate growth through consistently enhanced organic results and strategic M&A activity**

LONG-TERM GROWTH STRATEGY

Enhance Working Capital and Operational Capacity

- All Nova Ortho and Spine locations **currently operating at 35% capacity and turning away business**
- **Increased working capital** is expected to significantly **enhance operational capacity**

Expand Geographically into Southeast US

- **12 Nova Ortho and Spine locations** throughout Florida and Georgia
- **Expanding into broader Southeast US** through organic growth and strategic acquisitions


Grow into Contiguous Businesses via Accretive M&A

- **Complementary verticals to existing business** include MRI clinics, ambulatory surgery centers, etc.
- **Strategically deploying capital** to expand addressable market through **accretive M&A**

SUMMARY

Cardiff Lexington's Flywheel Effect

Building an innovative high growth model that profitably bridges the gap between underserved patients and healthcare providers



CARDIFF LEXINGTON
CORPORATION

Thank You

CARDIFF LEXINGTON
CORPORATION

APPENDIX

THIRD QUARTER & NINE MONTHS FINANCIAL HIGHLIGHTS

	Three Months Ended		Nine Months Ended	
	9/30/25	9/30/24	9/30/25	9/30/24
Revenue*	**$3,058,740**	**$1,355,641**	**$8,763,314**	**$5,149,416**
Cost of sales	$1,149,161	$1,000,601	$3,317,943	$2,741,765
Gross profit	**$1,909,579**	**$355,040**	**$5,445,371**	**$2,407,651**
Gross margin	*62.4%*	*26.1%*	*62.1%*	*46.8%*
Selling, general & administrative expense	$1,224,350	$936,835	$3,492,310	$2,622,981
Total operating expenses	$1,266,300	$940,200	$3,648,481	$2,933,302
Income (loss) from continuing operations	**$643,279**	**$(585,160)**	**$1,796,890**	**$525,651**
Net (loss)	$(1,144,299)	$(1,977,968)	$(2,821,471)	$(2,392,657)
Adjusted EBITDA**	**$663,179**	**$1,061,912**	**$1,916,821**	**$1,507,928**

CARDIFF LEXINGTON CORPORATION

*3Q24 revenue included a $1.7 million one-time charge to revenue for a change in accounting estimate of the billing settlement realization rate
**Adjusted EBITDA is a non-GAAP metric that is reconciled to GAAP net income in the appendix of this presentation

RECONCILIATION OF NON-GAAP METRICS

	Three months ended		Nine months ended	
	9/30/25	**9/30/24**	**9/30/25**	**9/30/24**
Net Income (loss) before discontinued operations	$(1,144,299)	$(1,977,968)	$(2,821,471)	$(2,281,345)
Adjustments to reconcile net income/(loss) to EBITDA				
Interest	1,765,528	1,386,041	4,594,714	1,803,657
Taxes	0	0	0	0
Depreciation	762	3,365	4,890	10,096
Amortization	0	0	0	24,821
EBITDA	**$621,991**	**$(588,562)**	**$1,778,133**	**$(442,771)**
Change in estimate for settlement realization rate	0	1,650,474	0	1,650,474
Stock compensation expense for shares issued	41,188	0	138,688	300,225
Adjusted EBITDA	**$663,179**	**$1,061,912**	**$1,916,821**	**$1,507,928**
Scaling and restructuring costs for business growth	0	76,110	11,676	180,302
Acquisition related costs	113,436	0	171,515	0
Adjusted EBITDA excluding other non-recurring costs	**$776,615**	**$1,138,022**	**$2,100,012**	**$1,688,230**

	Three months ended		Nine months ended	
	9/30/25	**9/30/24**	**9/30/25**	**9/30/24**
GAAP Revenue	$3,058,740	$1,355,641	$8,763,314	$5,149,416
Adjustments to claim settlement realization rate	-	1,650,474	-	2,849,629
Non-GAAP Adjusted Revenue	**$3,058,740**	**$3,006,115**	**$8,763,314**	**$7,999,045**

CARDIFF LEXINGTON CORPORATION